Article
AstraZeneca's Tagrisso slashes death risk in certain post-surgery lung cancer patients
Rating:
0.0
Views:
87
Likes:
1
Library:
1
AstraZeneca's lung cancer therapy, Tagrisso, cut the risk of death by more than half in patients with a certain form of lung cancer who were diagnosed early enough to have their tumour surgically removed, trial data showed.
Rate This Post
Rate The Educational Value
Rate The Ease of Understanding and Presentation
Interesting or Boring? Rate the Entertainment Value